单臂双抗(Single-arm BsAb):一种比较简单的结构,有两个不同的抗原结合部位。 双特异性T细胞连接抗体(BiTE,Bispecific T-cell Engager):一种特定类型的双抗,一端结合肿瘤细胞,另一端结合T细胞,促进免疫细胞直接攻击肿瘤细胞。 2. 作用机制: 双抗可以通过将免疫细胞(如T细胞或自然杀伤细胞)与肿瘤细胞或其他靶细胞...
Here, we review the principle of a new class of bispecific antibodies called BiTE (for "bispecific T-cell engager") antibodies. Recent results from clinical studies with a CD19/CD3-bispecific BiTE antibody suggest that this therapeutic paradigm is finally showing promise for treatment of both ...
三种类型的双特异性抗体:三功能抗体(trifunctional antibody),化学连接的Fab(chemically linked Fab)和双特异性T细胞接合物(bi-specific T-cell engager)。 蓝色和黄色部分区分单独的单克隆抗体。 1.1 IgG-like 该形式保留了两个Fab臂和一个Fc区的传统单克隆抗体(mAb)结构,除了两个Fab位点结合不同的抗原。 最常见...
Antiviral activity of HIV gp120-targeting bispecific T cell engager antibody constructs. J. Virol. 92, e00491–18 (2018). CAS PubMed PubMed Central Google Scholar Sloan, D. D. et al. Targeting HIV reservoir in infected CD4 T cells by dual-affinity re-targeting molecules (DARTs) that ...
The search strategy was based on the terms bispecific antibody, T cell engager, immune cell engager, antibody constructs, targeted delivery and variations of these terms. The ClinicalTrials.gov database was searched for trials evaluating bsAbs until September 5 2018, based on the abovementioned ...
Structures of bispecific T cell-recruiting antibodies. A bispecific T cell engager (BiTE) consists of two single-chain variable fragments (scFvs); a dual-affinity retargeting antibody (DART) consists of two engineered scFvs whose VH exchanged with the other one; a TandAb consists of two single...
Although numerous formats are currently in clinical development the only approved bispecific antibody fragment to date is blinatumomab (trade name Blincyto®) from Amgen. This is a bispecific T-cell engager or BiTE. BiTEs are constructed by genetic fusion of two single chain variable fragments (scF...
Intracellular tumor antigens presented on the cell surface in the context of human leukocyte antigen (HLA) molecules have been targeted by T cell-based therapies, but there has been little progress in developing small-molecule drugs or antibodies directed to these antigens. Here we describe a bi...
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J. Hematol. Oncol. 8, 111 (2015). Article PubMed PubMed Central Google Scholar Krupka, C. et al. Blockade of the PD-1/PD-L1 axis augments lysis...
The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an ext